Best Peptides for Brain Fog: Semax, Selank and the Blend Compared
The best peptides for brain fog ranked by real trial data. Semax, Selank and the Semax/Selank blend compared against the Russian clinical research and community reports.
The best peptides for brain fog are Semax and Selank, the two Russian nootropic peptides that have actually been through controlled human trials, plus the Semax/Selank blend that pairs them. Almost every other peptide marketed for mental clarity rests on rodent data or on nothing at all. This guide ranks each option by what the published research measured, then covers what thousands of community reports say about the parts the studies never tested.
Why Brain Fog Is Three Different Problems
Brain fog is a symptom, not a diagnosis, and the peptide that helps one version of it will do nothing for another. The published research on cognitive peptides splits along three pathways, and matching the pathway to your symptom is the difference between a protocol that works and an expensive placebo.
The first pathway is neurotrophic: the BDNF and trkB signaling system that governs how readily neurons form and maintain connections. Peptides acting here are studied for attention and working memory. Semax anchors this group.
The second is the stress and arousal axis. A brain running a constant background threat response spends its working memory on vigilance instead of on the task in front of you. Anxiety-driven fog is a resource allocation problem, not a neuron problem, and Selank targets it.
The third is metabolic. Mitochondrial output, cerebral blood flow and NAD+ availability all decline with age and inflammation, and cognition degrades with them. That overlaps heavily with the compounds covered in Peptide Mind's guide to peptides studied for energy.
Most people researching peptides for brain fog have some mix of all three. The ranking below is ordered by evidence quality, not by how common each problem is.
Best Peptides for Brain Fog, Ranked by Evidence
Ranked by the strength of published human data, the order is Semax, Selank, the Semax/Selank blend, Cerebrolysin, Dihexa, then the metabolic group. The gap between the top three and everything below is larger than most lists admit.
Peptide | Pathway | Strongest human evidence |
|---|---|---|
Semax | BDNF/trkB neurotrophic | Registered in Russia; n=110 stroke study, n=24 fMRI trial |
Selank | Enkephalin, GABAergic arousal | Two controlled trials vs benzodiazepines, n=62 and n=70 |
Semax/Selank blend | Both, in parallel | One fMRI connectivity study, n=52; no efficacy trial |
Cerebrolysin | Mixed neurotrophic fraction | Multiple RCTs in dementia and stroke, mixed results |
Dihexa | Hepatocyte growth factor/c-Met | None. Rodent only |
NAD+, MOTS-c | Mitochondrial and metabolic | Indirect; no cognitive endpoint trials |
1. Semax: The Most Studied Cognitive Peptide, With a Caveat
Semax is a synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) developed at the Institute of Molecular Genetics of the Russian Academy of Sciences in Moscow. It is an analog of the ACTH(4-10) fragment with the cortisol-releasing sequence removed, which is what separates it from a stress hormone.
Its mechanism is the best characterized in this category. Dolotov and colleagues found that a single 50 mcg/kg dose in rats produced measurable changes in the hippocampal neurotrophin system within hours.
A single application of Semax at 50 mcg/kg produced a maximal 1.4-fold increase in BDNF protein, a 1.6-fold increase in trkB tyrosine phosphorylation, and 3-fold and 2-fold increases in exon III BDNF and trkB mRNA respectively in the rat hippocampus. (Dolotov et al., Brain Research, 2006)
Semax has been registered and used clinically in Russia since the 1990s for ischemic stroke, cognitive decline and optic nerve disorders. Asmarin and colleagues, summarizing fifteen years of the peptide's development, reported that intranasal doses of 0.015 to 0.050 mg/kg improved operative memory and attention in healthy adults for 20 to 24 hours after a single administration, measured under conditions of extreme workload.
A 2018 imaging study gives the most direct evidence that the peptide reaches and changes the brain. Lebedeva's group at the Research Center of Mental Health in Moscow scanned 24 healthy volunteers with resting-state fMRI before, 5 minutes after and 20 minutes after intranasal 1% Semax or placebo. The Semax group showed a greater volume of the default mode network rostral subcomponent in the medial frontal cortex compared to controls.
The largest clinical dataset comes from stroke rehabilitation. Gusev, Martynov and colleagues at Pirogov Russian National Research Medical University followed 110 post-stroke patients over five months, giving two 10-day courses of 6,000 mcg/day intranasally separated by a 20-day interval. Semax raised plasma BDNF and accelerated functional recovery on the Barthel index regardless of when rehabilitation started.
Here is the caveat no competing article states: there is no PubMed-indexed randomized controlled trial of Semax for any indication. The stroke work was non-randomized, and the healthy volunteer data is decades old and thinly reported by Western standards. The mechanism is real and the Russian clinical use is genuine, but "used in Russian hospitals for 30 years" is a different claim from "proven in a double-blind trial." Peptide Mind's full Semax research guide covers the wider literature.
Shop research peptides
Live pricing from our top-rated vendor. Prices update as vendor listings change.
2. Selank: The Better Choice When Anxiety Is the Fog
Selank is a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) built from the endogenous immunopeptide tuftsin at the same Moscow institute. It is classed as an anxiolytic rather than a nootropic, and it has better controlled human evidence than Semax.
Its mechanism runs through the enkephalin system rather than direct GABA receptor binding, which is why it does not sedate. Zozulya and colleagues at the Center of Mental Health in Moscow found that patients with generalized anxiety had shortened enkephalin half-life, and that Selank dose-dependently inhibited enzymatic hydrolysis of plasma enkephalin.
The head-to-head trial is why Selank ranks this high. Sixty-two patients with generalized anxiety disorder and neurasthenia were assessed on the Hamilton, Zung and CGI scales, with 30 receiving Selank and 32 receiving medazepam, a benzodiazepine.
The anxiolytic effects of Selank and medazepam were similar, but Selank additionally produced antiasthenic and psychostimulant effects that the benzodiazepine did not. (Zozulia et al., Zhurnal Nevrologii i Psikhiatrii, 2008)
The most directly relevant finding for brain fog comes from a 2015 study that almost nobody cites. Medvedev's group compared phenazepam monotherapy in 30 patients against phenazepam plus Selank in 40 patients with anxiety-phobic and somatoform disorders, using the Stroop test and a verbal fluency test alongside the clinical scales. Adding Selank reduced the attention and memory impairment caused by the benzodiazepine, along with the sedation and asthenia, both during treatment and after the tranquilizer was withdrawn.
That is a direct measurement of a peptide clearing drug-induced cognitive fog, on validated instruments, in a controlled comparison. It is the strongest piece of brain fog evidence in this category, and it sits in a Russian-language journal that English-language peptide content has largely ignored.
The rodent work points the same direction. Kolik and colleagues at the Zakusov Research Institute of Pharmacology found that Selank at 0.3 mg/kg for 7 days prevented ethanol-induced memory and attention disturbances during alcohol withdrawal in rats.
3. The Semax/Selank Blend: Popular, Plausible, Barely Studied
The Semax/Selank blend is the most commonly used combination in this category and has almost no direct evidence behind it. What exists is one imaging study, and it is more interesting than the marketing copy suggests.
Panikratova and colleagues scanned 52 healthy participants with resting-state fMRI before, 5 and 20 minutes after receiving Semax, Selank or placebo, measuring functional connectivity from the amygdala and dorsolateral prefrontal cortex. The study found both general and specific effects of Selank and Semax on connectivity between the right amygdala and right temporal cortex, distinguishing the two peptides for the first time on a neuroimaging endpoint.
That result establishes something useful: the two peptides are not doing the same thing. Semax skews toward the executive and default mode networks, Selank toward the amygdala and threat circuitry. Combining them is mechanistically coherent for fog that has both an attention component and an anxiety component.
What no study has done is test the blend against either peptide alone on a cognitive outcome. The case for it is mechanism plus a large volume of consistent user reports, a weaker foundation than the case for either compound individually. Peptide Mind's Semax vs Selank comparison covers how the two differ in structure, onset and subjective effect.
4. Cerebrolysin: Real Trials, Mixed Results, Not a Peptide
Cerebrolysin is not a single peptide. It is a mixture of low-molecular-weight peptides and free amino acids produced by enzymatic breakdown of purified porcine brain protein, which puts it in a different regulatory and quality category entirely.
It has the most conventional trial evidence in this group. A 2024 three-year prospective study examined Cerebrolysin in preventive therapy of dementia in elderly patients with mild cognitive impairment, and a 2025 randomized pilot in Stroke tested it alongside speech therapy for post-stroke aphasia. Results across the literature are mixed.
For everyday brain fog in an otherwise healthy adult, it is a poor fit. It requires intramuscular or intravenous injection in courses, it is derived from animal brain tissue, and the trials supporting it studied dementia and stroke populations, not healthy people who feel foggy at 3pm.
5. Dihexa: Strong Rodent Data, Zero Human Data
Dihexa is an angiotensin IV analog developed at Washington State University, studied for its action on the hepatocyte growth factor and c-Met receptor system. In an APP/PS1 Alzheimer's mouse model it rescued cognitive impairment and recovered memory via PI3K/AKT signaling, and a 2018 systematic review in Neuroscience and Biobehavioral Reviews found consistent cognitive benefits for angiotensin IV analogs across experimental studies.
Shop research peptides
Live pricing from our top-rated vendor. Prices update as vendor listings change.
There are no human trials. None. Dihexa is frequently marketed with potency multiples relative to BDNF that trace to in vitro synaptogenesis assays, not to any measurement in a person. Its long-term human safety profile is unknown, and promoting new synapse formation is not a mechanism where unknown long-term effects should be shrugged off.
6. NAD+ and the Metabolic Group: Different Problem, Different Tool
NAD+, MOTS-c and SS-31 target mitochondrial function rather than neurotransmission, and none have been tested against a cognitive endpoint in a controlled trial. They appear on nearly every brain fog list because fatigue and fog travel together.
If your fog comes packaged with physical exhaustion, poor exercise recovery and afternoon crashes, the metabolic pathway is a reasonable target and the mechanism is sound. If your fog is purely cognitive and your energy is fine, this group is the wrong place to start.
What Community Reports Say That the Studies Do Not
The published research measures Barthel scores, plasma BDNF and Stroop performance. It says nothing about what these compounds feel like, how fast they work, or who they fail. Community reports across r/Peptides and r/Nootropics fill that gap, and several patterns recur often enough to be worth reporting. This section is anecdotal, not clinical.
Semax is described as clarity, not stimulation. The recurring account is sustained concentration rather than a caffeine-like lift, with one frequently referenced report describing "remarkable concentration" maintained far longer than usual. The most common negative is irritability at higher doses.
Selank onset is reported as fast in high-anxiety responders. Multiple accounts describe a noticeable change in reactivity within 15 to 30 minutes of the first intranasal dose, lowering the height of the anxiety spike and shortening recovery time rather than blunting emotion.
Response is highly individual, and non-responders are common. This is the most consistent theme in community reporting and the one no clinic blog mentions. Users with normal baseline anxiety frequently report feeling nothing from Selank, or report that it mutes drive. People already taking stimulants often report noticing nothing from Semax. One widely read personal review from a user on Adderall and heavy caffeine reported no effect from Semax at any dose between 0.25 mg and 1 mg, while finding the Semax and Selank combination noticeably effective on the one occasion they tried it together.
Semax can worsen anxiety in some people. Several detailed reports describe Semax amplifying an existing anxious state, in at least one case to the point of nightly panic attacks, resolving on discontinuation. Community consensus in those threads is to establish Selank first when anxiety dominates, then add Semax later at a low dose.
Intranasal is preferred over subcutaneous. Users who have tried both routes frequently report the nasal spray as more effective, which is also the route used in nearly all the Russian clinical work.
None of this is evidence in the sense the trials above are. It is a large, self-selected, unblinded sample with no control group. It is still the only data on the questions people actually ask, and the responder pattern recurs often enough to deserve stating plainly.
Dosing, Routes and Timing in the Research
Intranasal administration is the route used in nearly all published human work on both peptides, and the doses in circulation run considerably higher than those in the studies.
Peptide | Dose in published research | Route |
|---|---|---|
Semax | 0.015 to 0.050 mg/kg single dose; 6,000 mcg/day in the stroke protocol | Intranasal |
Selank | 0.3 mg/kg daily in rodent cognition work | Intranasal, intraperitoneal in animals |
Semax/Selank blend | No published dosing protocol | Intranasal |
Three points matter more than the numbers themselves.
The 6,000 mcg/day figure from the stroke trial is a therapeutic dose for acute neurological injury, delivered in two 10-day courses with a 20-day break. It is not a daily nootropic dose, and quoting it as a general protocol, which several vendor pages do, misreads the study.
The N-acetyl variants are different compounds with different pharmacokinetics. N-Acetyl Semax Amidate and N-Acetyl Selank Amidate carry terminal modifications that resist enzymatic degradation, and community dosing for them runs lower than for the base peptides. Peptide Mind covers this in its N-Acetyl Semax Amidate vs Semax comparison.
Timing follows the mechanism. Semax is dosed in the morning or early afternoon because its attention effects work against sleep onset. Selank carries a psychostimulant component alongside its anxiolytic one, which makes it a daytime compound despite the calming description, a point covered in Peptide Mind's best peptides for sleep guide. The peptide dosage calculator handles the reconstitution math.
Shop research peptides
Live pricing from our top-rated vendor. Prices update as vendor listings change.
Legal Status and the July 2026 FDA Vote
Neither Semax nor Selank is FDA-approved in the United States, and both are sold for research use only. That status shifted in July 2026 for one of them.
On July 24, 2026, the FDA Pharmacy Compounding Advisory Committee voted 8 to 5 with one abstention to recommend Semax for the 503A Bulks List, which governs what compounding pharmacies may legally use. Semax was one of six peptides the committee backed, alongside BPC-157, TB-500, KPV, MOTS-c and Epitalon.
Two qualifications matter. The vote is a recommendation, not binding on the FDA, and formal rulemaking takes months before any compounding becomes legal. And Selank was not part of it: its nomination was withdrawn in September 2024, removing it from Category 2 consideration entirely.
The FDA's own review noted that Semax was nominated for ADHD and as a nootropic, that supporting literature for the ADHD use could not be found, and that "nootropic" has no ICD-10 code and no professional society treatment guidelines. That is a fair summary of the evidence, and worth holding alongside the Russian clinical record.
Frequently Asked Questions
What peptide is best for brain fog?
Semax has the strongest overall case, with a well-mapped BDNF and trkB mechanism, human imaging data showing default mode network changes, and 30 years of clinical use in Russia. If your fog is driven by anxiety rather than by attention, Selank is the better match and actually has stronger controlled trial evidence, including a study measuring improved Stroop and verbal fluency performance.
Do peptides actually help brain fog?
Some have measured cognitive effects in controlled settings. Selank added to phenazepam reduced benzodiazepine-induced attention and memory impairment on the Stroop test in a study of 70 patients. Semax improved operative memory and attention in healthy adults at 0.015 to 0.050 mg/kg intranasally. No peptide has been tested against brain fog as a defined clinical endpoint, because brain fog is not a diagnosis.
Semax or Selank for brain fog?
Match the compound to the cause. Semax targets attention and executive function through the neurotrophic pathway and suits fog that feels like difficulty concentrating. Selank targets the arousal and threat circuitry and suits fog that comes with racing thoughts or chronic stress. A 52-participant fMRI study confirmed the two act on different networks, which is the strongest argument for choosing rather than guessing.
How long does Semax take to work?
Acute effects appear fast. The 2018 fMRI study measured default mode network changes 5 and 20 minutes after intranasal administration, and the 1997 human data reported attention and memory effects persisting 20 to 24 hours after a single dose. Community reports describe subjective focus changes within the first hour, with cumulative benefits over two to three weeks of consistent use.
Can peptides cause brain fog?
Yes, in two ways. Some users report that Selank mutes drive and mental sharpness rather than clearing it, particularly people whose baseline anxiety is already normal. And several community reports describe Semax amplifying anxiety in susceptible people, which produces its own cognitive interference. Stopping the compound resolves both in the reports available.
Are Semax and Selank FDA approved?
No. Neither is FDA-approved for any indication in the United States, and both are sold for research use only. In July 2026 an FDA advisory committee voted 8-5-1 to recommend Semax for the 503A compounding bulks list, which is a recommendation rather than an approval. Selank's nomination was withdrawn in September 2024. Both are registered medicines in Russia.
Can you take Semax and Selank together?
The combination is widely used and mechanistically coherent, since the two peptides act on different brain networks. No published study has tested the blend against either peptide alone on a cognitive outcome, so the support for it is mechanism plus user reports rather than trial data. Community consensus favors establishing Selank first when anxiety is the dominant symptom.
Shop research peptides
Live pricing from our top-rated vendor. Prices update as vendor listings change.
Choosing a Peptide for Your Version of Brain Fog
The best peptides for brain fog are Semax and Selank, and which one leads depends on whether your fog is an attention problem or an arousal problem. Weigh the Russian clinical record for what it is, a substantial body of work never replicated to Western randomized standards, and treat community reports as the unblinded, highly individual signal they are. Explore the research in Peptide Mind's Semax research guide and Semax vs Selank comparison.
References
Dolotov OV, Karpenko EA, Inozemtseva LS, et al. "Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus." Brain Research, 2006. PubMed 16996037.
Gusev EI, Martynov MY, Kostenko EV, Petrova LV, Bobyreva SN. "The efficacy of semax in the treatment of patients at different stages of ischemic stroke." Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova, 2018. PubMed 29798983.
Lebedeva IS, Panikratova YR, Sokolov OY, et al. "Effects of Semax on the Default Mode Network of the Brain." Bulletin of Experimental Biology and Medicine, 2018. PubMed 30225715.
Asmarin IP, Nezavibat'ko VN, Miasoedov NF, et al. "A nootropic adrenocorticotropin analog 4-10-semax (15 years experience in its design and study)." Zhurnal Vysshei Nervnoi Deiatelnosti imeni I.P. Pavlova, 1997. PubMed 9173745.
Zozulia AA, Neznamov GG, Siuniakov TS, et al. "Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia." Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova, 2008. PubMed 18454096.
Medvedev VE, Tereshchenko ON, Kost NV, et al. "Optimization of the treatment of anxiety disorders with selank." Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova, 2015. PubMed 26356395.
Zozulya AA, Kost NV, Sokolov OY, et al. "The inhibitory effect of Selank on enkephalin-degrading enzymes as a possible mechanism of its anxiolytic activity." Bulletin of Experimental Biology and Medicine, 2001. PubMed 11550013.
Panikratova YR, Lebedeva IS, Sokolov OY, et al. "Functional Connectomic Approach to Studying Selank and Semax Effects." Doklady Biological Sciences, 2020. PubMed 32342318.
Kolik LG, Nadorova AV, Antipova TA, et al. "Selank, Peptide Analogue of Tuftsin, Protects Against Ethanol-Induced Memory Impairment by Regulating of BDNF Content in the Hippocampus and Prefrontal Cortex in Rats." Bulletin of Experimental Biology and Medicine, 2019. PubMed 31625062.
Sun X, Deng Y, Fu X, Wang S, Duan R. "AngIV-Analog Dihexa Rescues Cognitive Impairment and Recovers Memory in the APP/PS1 Mouse via the PI3K/AKT Signaling Pathway." Brain Sciences, 2021. PubMed 34827486.
Ponomareva EV, Androsova LV, Krynskiy SA, Gavrilova SI. "Cerebrolysin in the preventive therapy of dementia in elderly patients with mild cognitive impairment: a three-year prospective comparative study." Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova, 2024. PubMed 39435777.
Disclaimer: The information on Peptide Mind is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. The peptides discussed are unapproved research chemicals for laboratory and research use only, not for human consumption. These statements have not been evaluated by the FDA, and nothing on this site is intended to diagnose, treat, cure, or prevent any disease. By accessing this site, you confirm you are 21 or older and agree to our Terms of Service.
Add a comment
This will be publicly visible.
Your email address will not be published.
Your comment will be reviewed by an admin before it is published.
